Explore 3 Stock Ideas & Industry Insights Download Free Report

Alzamend Neuro Inc

Company price
1.13 USD 0.02 ( 1.80%)
Last update at 2026-11-17T21:00:00Z
VOLUME
20487
Market Cap
4.22M

Momentum Score

…

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.12
Low
1.18
High
52 Week Price Range
0.84
Low
6.48
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Alzamend Neuro Inc is a clinical-stage biopharmaceutical company developing therapeutics for Alzheimer's disease and other neurodegenerative disorders. Its long-term growth may benefit from aging demographics, large unmet needs for disease-modifying treatments, and potential clinical or regulatory milestones that could validate its programs and advance commercialization prospects.
The company faces material risks from inherent clinical and regulatory uncertainty, likely need for continued capital, and intense competition in the neuroscience drug development sector.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.11
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.12
ROE
-249.97%
Net Debt
-3.95M
ROCE
-113.32%
Diluted EPS TTM
-3.67

Insight Announcement

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Income before tax -4.51M -9.95M -14.88M -12.36M -5.05M
Net income -4.51M -9.95M -14.88M -12.40M -5.20M
Selling general administrative 3.08M 3.48M 6.68M 7.12M 3.64M
Selling and marketing expenses - 0.25M 0.74M - -
Gross profit -0.05M -0.05M - - -
Reconciled depreciation 0.05M 0.05M 0.02M 0.00M -
Ebit -4.50M -9.94M -14.87M -12.32M -4.95M
Ebitda -4.45M -9.89M -14.85M -12.32M -4.95M
Depreciation and amortization 0.05M 0.05M 0.02M 0.00M 0.00M
Non operating income net other - - - 0.00M 0.06M
Operating income -4.50M -9.94M -14.87M -12.32M -4.95M
Other operating expenses 4.50M 9.94M 14.87M 12.32M 4.95M
Interest expense 0.02M 0.01M 0.01M 0.05M 0.16M
Interest income - - - 0.00M 0.00M
Net interest income -0.02M -0.01M -0.01M -0.05M -0.16M
Income tax expense - - - 0.04M 0.16M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 4.45M 9.94M 14.87M 12.32M 4.95M
Cost of revenue 0.05M 0.05M - - -
Total other income expense net -0.02M -0.01M -0.01M -0.04M -0.09M
Net income from continuing ops -4.51M -9.95M -14.88M -12.36M -5.05M
Net income applicable to common shares - - -14.88M -12.36M -5.05M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Total assets 4.60M 0.63M 5.92M 14.52M 2.91M
Other current assets 0.23M 0.08M 0.69M 0.35M 0.98M
Total liab 0.63M 3.23M 2.87M 1.16M 0.90M
Total stockholder equity 3.97M -2.59M 3.05M 13.35M 2.01M
Other current liab - 3.23M 2.87M 0.00M 0.06M
Common stock 0.00M 0.00M 0.01M 0.01M 0.01M
Capital stock 0.00M 0.00M 0.01M 0.01M 0.01M
Retained earnings -58.54M -54.02M -44.07M -29.19M -16.83M
Cash 3.95M 0.38M 5.14M 14.06M 1.93M
Total current liabilities 0.63M 3.23M 2.87M 1.16M 0.90M
Current deferred revenue - -3.23M - - -
Net debt -3.95M -0.08M -5.14M -14.06M -1.59M
Short term debt - 0.30M - - 0.34M
Short long term debt - 0.30M - - 0.34M
Short long term debt total - 0.30M - - 0.34M
Other stockholder equity 62.50M 51.43M 47.11M 42.54M 18.84M
Property plant equipment - - 0.08M 0.10M -
Total current assets 4.18M 0.46M 5.84M 14.41M 2.91M
Net tangible assets - - 3.05M 13.35M 2.01M
Net receivables - - - - 0.02M
Inventory - - - - -0.02M
Accounts payable 0.63M 2.93M 2.87M 1.16M 0.50M
Accumulated other comprehensive income - 0.00M - - -
Common stock total equity - - 0.01M 0.01M 0.01M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - -44.07M -29.19M -16.83M
Non current assets total 0.43M 0.18M 0.08M 0.10M 0.00M
Breakdown 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Type yearly yearly yearly yearly yearly
Date 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Investments -0.30M -0.15M 0.00M -0.11M 0.10M
Change to liabilities - - 1.71M 0.69M -0.41M
Total cashflows from investing activities -0.30M -0.15M - -0.11M 0.10M
Net borrowings 0.00M 0.30M - -0.06M 2.25M
Total cash from financing activities 10.44M 3.65M 0.00M 18.85M 4.45M
Change to operating activities - - 0.64M 0.63M 0.26M
Net income -4.51M -9.95M -14.88M -12.36M -5.05M
Change in cash 3.57M -4.76M -8.92M 12.13M 1.84M
Begin period cash flow 0.38M 5.14M 14.06M 1.93M 0.09M
End period cash flow 3.95M 0.38M 5.14M 14.06M 1.93M
Total cash from operating activities -6.57M -8.27M -8.92M -6.61M -2.71M
Issuance of capital stock 10.44M 3.35M 0.00M 18.91M 2.10M
Depreciation 0.05M 0.05M 0.02M 0.00M 0.12M
Other cashflows from investing activities - - - -0.11M 0.10M
Sale purchase of stock - - 0.00M 6.00M 2.10M
Other cashflows from financing activities 7.74M 2.10M -0.99M 0.00M 2.35M
Change to netincome - - 3.58M 4.40M 2.49M
Capital expenditures 0.30M 0.15M 0.00M 0.11M 0.11M
Cash flows other operating - - 0.64M 0.63M 0.65M
Cash and cash equivalents changes - - -8.92M 12.13M 1.84M
Change in working capital -2.44M 0.67M 2.35M 1.33M -0.15M
Stock based compensation 0.33M 0.96M 3.58M 4.41M 2.03M
Other non cash items 0.01M 0.00M 1.71M 0.01M 0.45M
Free cash flow -6.87M -8.42M -8.92M -6.72M -2.71M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
ALZN
Alzamend Neuro Inc
0.02
1.80%
1.13 - - - 1.93 -3.13
NVO
Novo Nordisk A/S
-0.99
2.39%
40.60 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc
-3.90
0.73%
533.89 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc
5.36
0.56%
957.76 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE
-
-%
965.00 45.77 31.25 13.84 7.12 36.06

Profile*

Alzamend Neuro Inc

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

3480 Peachtree Road NE, Atlanta, GA, United States, 30326

844 722 6333

4

Name Title Year Born
Mr. Stephan Jackman CEO & Director 1976
Mr. Kenneth S. Cragun CPA Sr. VP of Fin. 1961
Mr. David J. Katzoff Chief Financial Officer 1962
Mr. Henry C. W. Nisser Esq. Exec. VP, Gen. Counsel & Director 1969
Mr. Stephan Jackman CEO & Director 1977
Mr. David J. Katzoff Chief Financial Officer 1963
Mr. Milton Charles Ault III Founder & Vice Chairman 1970
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 1970
Mr. Kenneth S. Cragun CPA Senior Vice President of Finance 1961
Mr. Henry C. W. Nisser Esq. Executive VP, General Counsel & Director 1969

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…